SGLT-2 Inhibitors in Heart Failure and Type-2 Diabetes: Hitting Two Birds with One Stone?

被引：25

作者：

Santos-Ferreira, Diogo ^{[1
,2
]}

Goncalves-Teixeira, Pedro ^{[1
,2
]}

Fontes-Carvalho, Ricardo ^{[1
,2
]}

机构：

[1] Ctr Hosp Vila Nova de Gaia Espinho, Serv Cardiol, Porto, Portugal

[2] Univ Porto, Fac Med, Dept Cirurgia & Fisiol, Unidade Invest Cardiovasc, PT-4200319 Porto, Portugal

来源：

CARDIOLOGY | 2020年 / 145卷 / 05期

关键词：

Diabetes mellitus; Type 2 diabetes mellitus; Diabetic cardiomyopathies; Heart failure; Chronic heart failure; Preventive cardiology; Sodium-glucose transporter 2 inhibitors; GLUCOSE-LOWERING DRUGS; CARDIOVASCULAR MORTALITY; INSULIN-RESISTANCE; GLYCEMIC CONTROL; LOWER RISK; CVD-REAL; EMPAGLIFLOZIN; MELLITUS; HOSPITALIZATION; NEPHROPATHY;

D O I：

10.1159/000504694

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Type 2 diabetes mellitus (T2DM) and heart failure (HF) have a tremendous impact worldwide, markedly reducing life-expectancy and quality of life. It is now known that each disease represents a risk factor for the other. Moreover, when they are combined, the prognosis is significantly worse. Until recently, these pathologies have been managed independently. However, their treatment paradigm is rapidly changing, with recent cardiovascular outcome trials showing that sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are effective in the management of both diseases. This article explores the interactions between T2DM and HF and the concept of diabetic cardiomyopathy and summarizes recent data regarding the effects of SGLT-2i on HF hospitalization and the proposed pathophysiological mechanisms involved.

引用

页码：311 / 320

页数：10

共 83 条

[51] EMPAGLIFLOZIN INDUCES A MYOCARDIAL METABOLIC SHIFT FROM GLUCOSE CONSUMPTION TO KETONE METABOLISM THAT MITIGATES ADVERSE CARDIAC REMODELING AND IMPROVES MYOCARDIAL CONTRACTILITY [J].

Santos-Gallego, Carlos G. ;

Ibanez, Juan Antonio Requena ;

Antonio, Rodolfo San ;

Ishikawa, Kiyotake ;

Watanabe, Shin ;

Botija, Maria Belen Picatoste ;

Salvo, Angel Javier Sanz ;

Hajjar, Roger ;

Fuster, Valentin ;

Badimon, Juan .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 71 (11) :674-674

[52] Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality Insights From the EMPA-REG OUTCOME Trial [J].

Savarese, Gianluigi ;

Sattar, Naveed ;

Januzzi, James ;

Verma, Subodh ;

Lund, Lars H. ;

Fitchett, David ;

Zeller, Cordula ;

George, Jyothis T. ;

Brueckmann, Martina ;

Ofstad, Anne Pernille ;

Inzucchi, Silvio E. ;

Wanner, Christoph ;

Zinman, Bernard ;

Butler, Javed .

CIRCULATION, 2019, 139 (11) :1458-1460

[53] Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics [J].

Scheen, A. J. .

DIABETES & METABOLISM, 2016, 42 (04) :224-233

[54] Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium Glucose Co-Transporter 2 Inhibitor [J].

Scheen, Andre J. .

CLINICAL PHARMACOKINETICS, 2014, 53 (03) :213-225

[55] Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus [J].

Sha, S. ;

Polidori, D. ;

Heise, T. ;

Natarajan, J. ;

Farrell, K. ;

Wang, S. -S. ;

Sica, D. ;

Rothenberg, P. ;

Plum-Moerschel, L. .

DIABETES OBESITY & METABOLISM, 2014, 16 (11) :1087-1095

[56] Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people [J].

Shah, Anoop Dinesh ;

Langenberg, Claudia ;

Rapsomaniki, Eleni ;

Denaxas, Spiros ;

Pujades-Rodriguez, Mar ;

Gale, Chris P. ;

Deanfield, John ;

Smeeth, Liam ;

Timmis, Adam ;

Hemingway, Harry .

LANCET DIABETES & ENDOCRINOLOGY, 2015, 3 (02) :105-113

[57] p53-Induced Adipose Tissue Inflammation Is Critically Involved in the Development of Insulin Resistance in Heart Failure [J].

Shimizu, Ippei ;

Yoshida, Yohko ;

Katsuno, Taro ;

Tateno, Kaoru ;

Okada, Sho ;

Moriya, Junji ;

Yokoyama, Masataka ;

Nojima, Aika ;

Ito, Takashi ;

Zechner, Rudolf ;

Komuro, Issei ;

Kobayashi, Yoshio ;

Minamino, Tohru .

CELL METABOLISM, 2012, 15 (01) :51-64

[58] Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes [J].

Shin, Seok Joon ;

Chung, Sungjin ;

Kim, Soo Jung ;

Lee, Eun-Mi ;

Yoo, Young-Hye ;

Kim, Ji-Won ;

Ahn, Yu-Bae ;

Kim, Eun-Sook ;

Moon, Sung-Dae ;

Kim, Myung-Jun ;

Ko, Seung-Hyun .

PLOS ONE, 2016, 11 (11)

[59] Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study [J].

Stratton, IM ;

Adler, AI ;

Neil, HAW ;

Matthews, DR ;

Manley, SE ;

Cull, CA ;

Hadden, D ;

Turner, RC ;

Holman, RR .

BMJ-BRITISH MEDICAL JOURNAL, 2000, 321 (7258) :405-412

[60] Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice [J].

Suzuki, Masayuki ;

Honda, Kiyofumi ;

Fukazawa, Masanori ;

Ozawa, Kazuharu ;

Hagita, Hitoshi ;

Kawai, Takahiro ;

Takeda, Minako ;

Yata, Tatsuo ;

Kawai, Mio ;

Fukuzawa, Taku ;

Kobayashi, Takamitsu ;

Sato, Tsutomu ;

Kawabe, Yoshiki ;

Ikeda, Sachiya .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2012, 341 (03) :692-701

← 1 2 3 4 5 6 7 8 9 →